CNAT News and Press, Conatus Pharmaceuticals From 03/19/19

Quick Take Genfit S.A. ( GNFT ) intends to raise $130 million in a global IPO from the sale of ADSs representing underlying ordinary shares, per an amended registration statement . The company is developing treatments for non-alcoholic steatohepatitis [NASH] conditions. GNFT expects Pha...

Nano cap Conatus Pharmaceuticals ( CNAT +22.2% ) is up on more than a 4x surge in volume. Shares have rallied  43%  this week. More news on: Conatus Pharmaceuticals Inc., Madrigal Pharmaceuticals, Inc., Viking Therapeutics, Inc., Healthcare stocks news, Stocks on the move, ...

Gainers:  Akari Therapeutics (NASDAQ: AKTX ) +177% . Pareteum Corporation (NASDAQ: TEUM ) +26% . Clean Energy Fuels (NASDAQ: CLNE ) +25% . Guardant Health (NASDAQ: GH ) +24% . Vera Bradley (NASDAQ: VRA ) +21% . Natera (NASDAQ: NTRA ) +20% . Conatus Pharmaceuticals (NASDAQ: CNAT ...

Akari Therapeutics (NASDAQ: AKTX ) +19%  on announcing that it had a successful Type B, pre-IND meeting with the FDA. More news on: Akari Therapeutics, Plc, Pareteum Corporation, PAVmed Inc., Stocks on the move, Read more ...

SAN DIEGO, March 13, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today the acceptance of an abstract for a late-breaker oral presentation at The International Liver Congress™ 2019, the Annual Meeting of the European Association for the Study of the ...

SAN DIEGO, March 01, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the fourth quarter and full year ended December 31, 2018, after the market close on Friday, March 8, 2019. Conatus will host a conference call a...

Quick Take Genfit S.A. ( GNFT ) intends to raise $100 million in an IPO of ADSs representing ordinary shares, according to an F-1 registration statement . The firm is developing treatment candidates for non-alcoholic steatohepatitis [NASH] conditions. GNFT says it expects results from i...

Investment Thesis Conatus ( CNAT ) is a small-cap ($59M) liver therapeutics Pharmaceuticals founded in 2005 by Drs. Steven Mento and Alfred Spada. Emricasan (IDN-6556, PF-03491390) is an oral irreversible pan-caspase inhibitor with dual anti-apoptotic and anti-inflammatory effects. In Dece...

Author’s note: I am grateful to CEO & President, Dr. Steve Mento and management, for granting me the interview. Introduction Conatus Pharmaceuticals ( CNAT ) is a small cap ($59M) clinical stage biopharma. Emricasan, a dual anti-apoptotic/anti-inflammatory oral irreversibl...

My previous article forecast problems for selonsertib, as new research indicates that this drug targets mouse-specific pathways that are not present in humans. NASH cirrhosis trials continue to struggle. Intercept’s Ocaliva, a “NASH cirrhosis” drug candidate, is haile...